Baseline characteristics of patients who did and did not enter the BENEFIT Extension study (A) at the start of the placebo-controlled phase of BENEFIT and (B) at the start of the extension study
| (A) | Baseline characteristics | |||||
|---|---|---|---|---|---|---|
| Did not enter BENEFIT extension | Entered BENEFIT extension | |||||
| Early treatment | Delayed treatment | Overall | Early treatment | Delayed treatment | Overall | |
| n | 114 | 70 | 184 | 178 | 106 | 284 |
| Age (years), median (Q1–3) | 29.0 (24.0–38.0) | 30.5 (27.0–37.0) | 30.0 (25.0–37.0) | 30.0 (24.0–37.0) | 30.0 (24.0–35.0) | 30.0 (24.0–36.5) |
| Female, % | 70.2 | 70.0 | 70.1 | 71.3 | 70.8 | 71.1 |
| Multifocal onset, % | 42.1 | 48.6 | 44.6 | 51.1 | 46.2 | 49.3 |
| Steroid treatment at first event, % | 75.4 | 70.0 | 73.4 | 69.1 | 69.8 | 69.4 |
| Number of T2 lesions, median (Q1–3) | 18.0 (8.0–36.0) | 18.5 (6.0–34.0) | 18.0 (7.0–35.5) | 18.0 (7.0–39.0) | 16.0 (8.0–37.0) | 17.0 (7.0–38.5) |
| Number of Gd-enhancing lesions, median (Q1–3) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) | 0.0 (0.0–1.0) |
| EDSS at baseline median (mean), Q1–3 | 1.5 (1.64), 1.0–2.0 | 1.5 (1.53), 1.0–2.0 | 1.5 (1.60), 1.0–2.0 | 1.5 (1.55), 1.0–2.0 | 1.5 (1.46), 1.0–2.0 | 1.5 (1.52), 1.0–2.0 |
| At start of extension study | ||||||
| Did not enter BENEFIT extension | Entered BENEFIT extension | |||||
| (B) | Early treatment | Delayed treatment | Overall | Early treatment | Delayed treatment | Overall |
| n | 114 | 70 | 184 | 178 | 106 | 284 |
| CDMS, n (%) | 40 (35.1) | 34 (48.6) | 74 (40.2) | 84 (47.2) | 60 (56.6) | 144 (50.7) |
| McDonald MS,n (%) | 81 (71.1) | 56 (80.0) | 137 (74.5) | 144 (80.9) | 98 (92.5) | 242 (85.2) |
| EDSS, median (mean), Q1–3 | 1.5 (1.55), 1.0–2.0 | 1.5 (1.67), 1.0–2.0 | 1.5 (1.60), 1.0–2.0 | 1.5 (1.51), 1.0–2.0 | 1.5 (1.51), 1.0–2.0 | 1.5 (1.51), 1.0–2.0 |
CDMS, clinically definite multiple sclerosis; EDSS, Expanded Disability Status Scale; Gd, gadolinium; MS, multiple sclerosis; Q1–3, 1st to 3rd quartile.